A new study published in The Annals of Pharmacotherapy found that phenylephrine may not be as effective as previously thought, with some studies showing no significant benefit. The study's findings suggest that higher doses of the drug could increase the risk of adverse effects, and the FDA is urged to require additional research.
A first published analysis of the FDA's mifepristone reports reveals 607 adverse events, including fatalities from bleeding or septic shock. The authors call for increased research into allergic and fatal septic reactions and propose measures to improve safety monitoring.
Researchers propose a mechanism by which mifepristone increases the risk of fatal C. sordellii infections, including septic shock and death. The antiprogesterone effects of mifepristone may disrupt immune function, allowing bacteria to thrive in the cervical canal.
A new study published in Annals of Pharmacotherapy found that beta blockers reduced hospital stays and atrial fibrillation by 59% and 55%, respectively. Early use of beta-blockers also led to significant reductions in patient death, fluid in the lungs, and need for a balloon pump.
Experts dispute FDA warnings on antidepressants and suicidal risk, citing limited data for children and adolescents. Studies show a decrease in suicides over years of growing SSRI use, but caution is advised when interpreting the data.
Studies suggest that over-the-counter 'Plan B' emergency contraception may lead to increased risk-taking behaviors and reduced comprehensive healthcare access for US women. The drug has an 11-25% failure rate, resulting in additional pregnancies and abortions.